Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gabapentin enacarbil
Drug ID BADD_D00982
Description Gabapentin enacarbil is marketed under the name Horizant. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
Indications and Usage For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
Marketing Status Prescription
ATC Code N03AX12
DrugBank ID DB08872
KEGG ID D09539
MeSH ID C493250
PubChem ID 9883933
TTD Drug ID D05KBU
NDC Product Code 53451-0103; 70966-0011; 49187-0710; 53451-0101; 66039-945
Synonyms 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid | gabapentin enacarbil | XP 12464 | XP12464 | XP-12464 | XP 10569 | XP10569 | XP-10569 | XP 11239 | XP11239 | XP-11239 | XP 13512 | XP13512 | XP-13512 | XP 11084 | XP11084 | XP-11084
Chemical Information
Molecular Formula C16H27NO6
CAS Registry Number 478296-72-9
SMILES CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Libido decreased21.03.02.005; 19.08.03.001--
Loss of consciousness17.02.04.0040.006362%Not Available
Malaise08.01.01.0030.012723%
Metabolic acidosis14.01.01.0030.006362%Not Available
Mood altered19.04.02.0070.006362%Not Available
Myocardial ischaemia24.04.04.010; 02.02.02.0080.001660%Not Available
Myoclonus17.02.05.0080.063617%Not Available
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.0060.009543%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.006362%
Oral discomfort07.05.05.0010.006362%Not Available
Oral pain07.05.03.0020.009543%
Renal disorder20.01.02.0020.006362%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.006362%Not Available
Rhabdomyolysis15.05.05.0020.009543%
Sedation17.02.04.005--Not Available
Somnolence19.02.05.003; 17.02.04.0060.015904%
Suicidal ideation19.12.01.0030.006362%
Swelling08.01.03.0150.006362%Not Available
Tongue spasm07.14.02.0080.044532%Not Available
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred17.17.01.010; 06.02.06.007--
Weight increased13.15.01.006--
Balance disorder17.02.02.007--Not Available
Dysstasia17.02.02.0120.006362%Not Available
Musculoskeletal stiffness15.03.01.0050.006362%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.006362%
Eye movement disorder17.02.05.025; 06.05.02.0080.044532%Not Available
Drug intolerance08.06.01.0130.006362%Not Available
Unevaluable event08.01.03.0510.006362%Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages